Buspirone: Difference between revisions
| [unchecked revision] | [checked revision] |
MDElliottMD (talk | contribs) Auto-created stub |
MDElliottMD (talk | contribs) parser-claude: Buspirone MedTemplate refill, Top 300 stub upgrade |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{MedTemplate | {{MedTemplate | ||
| generic = Buspirone | | generic = Buspirone | ||
| brand = Buspar | | brand = Buspar (US brand discontinued; generic widely available) | ||
| classes = Anxiolytic | | structure = | ||
| mechanism = 5-HT1A partial agonist; | | classes = [[:Category:Anxiolytics|Anxiolytic]], [[:Category:Azapirones|Azapirone]], [[:Category:Serotonin 5-HT1A partial agonists|Serotonin 5-HT1A partial agonist]] | ||
| uses = <vote slug="generalized-anxiety-disorder-use">Generalized anxiety disorder (FDA)</vote>, <vote slug="depression-adjunct-buspirone-use">Depression adjunct to SSRI/SNRI (off-label)</vote>, <vote slug="ssri-sexual-dysfunction-adjunct-use">SSRI-induced sexual dysfunction (off-label adjunct, weak evidence)</vote>, <vote slug="bruxism-use">Sleep-related bruxism (off-label)</vote> | |||
| starting_dose = 5 mg PO TID or 7.5 mg PO BID; titrate by 5 mg every 2-3 days to clinical effect, commonly 30-60 mg/day divided BID-TID | |||
| preparations = Tablets 5, 7.5, 10, 15, 30 mg (the 15 and 30 mg tablets are scored for halving and quartering) | |||
| fda_max = 60 mg/day | |||
| pill_id = | |||
| routes = Oral | |||
| onset = '''Anxiolytic effect emerges over 2-4 weeks'''; buspirone does NOT work for acute anxiety, which is the central teaching point and the most common cause of treatment failure | |||
| duration = ~8 hours (TID dosing) | |||
| halflife = Buspirone 2-3 hours; 1-PP active metabolite 4-6 hours<ref name="buspar-label">FDA Prescribing Information, Buspar (buspirone hydrochloride), Bristol-Myers Squibb/various, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018731s051lbl.pdf</ref> | |||
| bioavailability = ~4% (extensive first-pass metabolism)<ref name="buspar-label" /> | |||
| pregnancy = Limited human data; older agent with substantial use experience and no clear teratogenic signal.{{citation needed}} | |||
| legal = [[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, which is a meaningful clinical advantage over benzodiazepine alternatives for chronic anxiety<ref name="buspar-label" /> | |||
| mechanism = <vote slug="buspirone-mech-claim">Serotonin 5-HT1A receptor partial agonist (acts at both presynaptic autoreceptors and postsynaptic sites) with weak dopamine D2 receptor antagonism. '''No GABA receptor activity''', so buspirone has no sedation, no muscle relaxation, no tolerance to anxiolytic effect, no withdrawal syndrome, no dependence liability, and no controlled-substance status, distinguishing it sharply from the benzodiazepines.</vote> Strong CYP3A4 substrate: grapefruit juice, ketoconazole, erythromycin, and clarithromycin substantially raise plasma exposure; rifampin and St. John's wort lower it. The 2-4 week onset means buspirone is appropriate for chronic GAD-style anxiety but not acute anxiety<ref name="buspar-label" />. | |||
}} | }} | ||
== References == | |||
<references /> | |||
[[Category:Anxiolytics]] | [[Category:Anxiolytics]] | ||
[[Category:Azapirones]] | |||
[[Category:Serotonin 5-HT1A partial agonists]] | |||
Latest revision as of 06:33, 23 May 2026
Buspirone
Buspar (US brand discontinued; generic widely available)
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Generalized anxiety disorder (FDA)0, Depression adjunct to SSRI/SNRI (off-label)0, SSRI-induced sexual dysfunction (off-label adjunct, weak evidence)0, Sleep-related bruxism (off-label)0
Pharmacy
Starting dose
5 mg PO TID or 7.5 mg PO BID; titrate by 5 mg every 2-3 days to clinical effect, commonly 30-60 mg/day divided BID-TID
Preparations
Tablets 5, 7.5, 10, 15, 30 mg (the 15 and 30 mg tablets are scored for halving and quartering)
US FDA Max
60 mg/day
Pharmacology
Routes
Oral
Onset
Anxiolytic effect emerges over 2-4 weeks; buspirone does NOT work for acute anxiety, which is the central teaching point and the most common cause of treatment failure
Duration
~8 hours (TID dosing)
Half-life
Buspirone 2-3 hours; 1-PP active metabolite 4-6 hours[1]
Bioavailability
~4% (extensive first-pass metabolism)[1]
Pregnancy
Limited human data; older agent with substantial use experience and no clear teratogenic signal.[citation needed]
Legal status
Purported mechanism
Serotonin 5-HT1A receptor partial agonist (acts at both presynaptic autoreceptors and postsynaptic sites) with weak dopamine D2 receptor antagonism. No GABA receptor activity, so buspirone has no sedation, no muscle relaxation, no tolerance to anxiolytic effect, no withdrawal syndrome, no dependence liability, and no controlled-substance status, distinguishing it sharply from the benzodiazepines.0 Strong CYP3A4 substrate: grapefruit juice, ketoconazole, erythromycin, and clarithromycin substantially raise plasma exposure; rifampin and St. John's wort lower it. The 2-4 week onset means buspirone is appropriate for chronic GAD-style anxiety but not acute anxiety[1].
References
- ↑ 1.0 1.1 1.2 1.3 FDA Prescribing Information, Buspar (buspirone hydrochloride), Bristol-Myers Squibb/various, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018731s051lbl.pdf